Literature DB >> 27906872

Role of Combined 68Ga-DOTATOC and 18F-FDG Positron Emission Tomography/Computed Tomography in the Diagnostic Workup of Pancreas Neuroendocrine Tumors: Implications for Managing Surgical Decisions.

Sara Cingarlini1, Silvia Ortolani, Matteo Salgarello, Giovanni Butturini, Anna Malpaga, Veronica Malfatti, Mirko DʼOnofrio, Maria Vittoria Davì, Paola Vallerio, Andrea Ruzzenente, Paola Capelli, Elia Citton, Elisabetta Grego, Chiara Trentin, Riccardo De Robertis, Aldo Scarpa, Claudio Bassi, Giampaolo Tortora.   

Abstract

OBJECTIVES: Ga-DOTATOC (Ga) positron emission tomography (PET)/computed tomography (CT) is recommended in the workup of pancreas neuroendocrine tumors (PanNETs); evidence suggests that F-FDG (F) PET/CT can also provide prognostic information. Aims of this study were to assess the role of combined Ga- and F-PET/CT in the evaluation of grade (G) 1-2 PanNETs and to test the correlation between F-PET/CT positivity and tumor grade.
METHODS: Preoperative Ga- and F-PET/CT of 35 patients with surgically resected G1-2 PanNETs were evaluated. For grading, the 2010 World Health Organization Classification was used; an ancillary analysis with Ki67 cutoffs at 5% to 20% was conducted. Correlation between F-PET/CT positivity (SUVmax > 3.5) and grade was assessed.
RESULTS: Of 35 PanNETs, 28.6% and 71.4% were G1 and G2 as per World Health Organization. Ga-PET/CT showed high sensitivity (94.3%) in detecting G1-2 PanNETs. F-PET/CT was positive in 20% and 76% G1 and G2 tumors (P = 0.002). F-PET/CT identified G2 PanNETs with high positive predictive value (PPV, 90.5%). F-PET/CT correlated with tumor grade also in the ancillary analysis (P = 0.009).
CONCLUSIONS: The high sensitivity of Ga-PET/CT in NET detection is known. The high PPV of F-PET/CT in the identification of G2 forms suggests its potential role in PanNETs prognostication and risk stratification.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 27906872     DOI: 10.1097/MPA.0000000000000745

Source DB:  PubMed          Journal:  Pancreas        ISSN: 0885-3177            Impact factor:   3.327


  12 in total

Review 1.  Systematic Review and Metaanalysis of Lymph Node Metastases of Resected Pancreatic Neuroendocrine Tumors.

Authors:  Masayuki Tanaka; Max Heckler; André L Mihaljevic; Pascal Probst; Ulla Klaiber; Ulrike Heger; Simon Schimmack; Markus W Büchler; Thilo Hackert
Journal:  Ann Surg Oncol       Date:  2020-07-27       Impact factor: 5.344

Review 2.  Imaging of pancreatic neuroendocrine tumors: recent advances, current status, and controversies.

Authors:  Lingaku Lee; Tetsuhide Ito; Robert T Jensen
Journal:  Expert Rev Anticancer Ther       Date:  2018-07-17       Impact factor: 4.512

3.  Clinical Usefulness of 18F-Fluorodeoxyglucose Positron Emission Tomography in the Diagnostic Algorithm of Advanced Entero-Pancreatic Neuroendocrine Neoplasms.

Authors:  Maria Rinzivillo; Stefano Partelli; Daniela Prosperi; Gabriele Capurso; Patrizia Pizzichini; Elsa Iannicelli; Elettra Merola; Francesca Muffatti; Francesco Scopinaro; Orazio Schillaci; Matteo Salgarello; Massimo Falconi; Gianfranco Delle Fave; Francesco Panzuto
Journal:  Oncologist       Date:  2017-11-08

Review 4.  Imaging of neuroendocrine tumors: A pictorial review of the clinical value of different imaging modalities.

Authors:  Ali Pirasteh; Petra Lovrec; Lisa Bodei
Journal:  Rev Endocr Metab Disord       Date:  2021-03-30       Impact factor: 9.306

5.  Flushing as atypical initial presentation of functional gallbladder neuroendocrine carcinoma: A case report.

Authors:  Ming Jin; Bo Zhou; Xiong-Ling Jiang; Qi-Yi Zhang; Xiang Zheng; Yuan-Cong Jiang; Sheng Yan
Journal:  World J Gastroenterol       Date:  2020-02-14       Impact factor: 5.742

6.  Spontaneous rupture of solid pseudopapillary tumor of pancreas: A case report and review of literature.

Authors:  Xiaofeng Xu; Diyu Chen; Linping Cao; Xiaode Feng; Rongliang Tong; Shusen Zheng; Jian Wu
Journal:  Medicine (Baltimore)       Date:  2019-11       Impact factor: 1.817

7.  Prediction of the aggressiveness of non-functional pancreatic neuroendocrine tumors based on the dual-tracer PET/CT.

Authors:  Susanna Majala; Hanna Seppänen; Jukka Kemppainen; Jari Sundström; Camilla Schalin-Jäntti; Risto Gullichsen; Jukka Schildt; Harri Mustonen; Tiina Vesterinen; Johanna Arola; Saila Kauhanen
Journal:  EJNMMI Res       Date:  2019-12-23       Impact factor: 3.138

Review 8.  Role of PET/CT and Therapy Management of Pancreatic Neuroendocrine Tumors.

Authors:  Diletta Calabrò; Giulia Argalia; Valentina Ambrosini
Journal:  Diagnostics (Basel)       Date:  2020-12-07

9.  Correlation of Somatostatin Receptor 1-5 Expression, [68Ga]Ga-DOTANOC, [18F]F-FDG PET/CT and Clinical Outcome in a Prospective Cohort of Pancreatic Neuroendocrine Neoplasms.

Authors:  Susanna Majala; Tiina Vesterinen; Hanna Seppänen; Harri Mustonen; Jari Sundström; Camilla Schalin-Jäntti; Risto Gullichsen; Jukka Schildt; Jukka Kemppainen; Johanna Arola; Saila Kauhanen
Journal:  Cancers (Basel)       Date:  2021-12-29       Impact factor: 6.639

10.  The NETPET Score: Combining FDG and Somatostatin Receptor Imaging for Optimal Management of Patients with Metastatic Well-Differentiated Neuroendocrine Tumors.

Authors:  Elif Hindié
Journal:  Theranostics       Date:  2017-03-01       Impact factor: 11.556

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.